Doctors Express ‘Huge Shock’ as Manufacturer Pulls Popular Asthma Inhalers From Market

Published on December 29, 2023

Biopharma corporation GSK (formerly GlaxoSmithKline) will cease the manufacture and sale of two extremely popular branded asthma inhalers beginning next year in favor of producing generic versions, triggering concerns about insurance coverage and product access. Effective Jan. 1, GSK will discontinue its asthma inhaler Flovent HFA and inhalation powder Flovent Diskus. Instead, the company will be offering generic versions of these products at a lower cost. The generic version of Flovent HFA was launched in May 2022. Discontinuation of Flovent HFA has raised concerns among medical experts as this is happening amid the respiratory virus season. Many insurers may not provide coverage for the generic version of the product....